Oxybutynin

Excerpt

Oxybutynin, an anticholinergic medication, is approved by the U.S. Food and Drug Administration (FDA) and is indicated for patients with overactive bladder or symptoms of detrusor overactivity, such as urinary frequency and urgency. Oxybutynin works through competitive acetylcholine antagonism at postganglionic muscarinic receptors, leading to the relaxation of the smooth muscles of the bladder. This medication has been thoroughly researched and approved for use in patients aged 5 and older. In addition, oxybutynin is recommended for individuals who experience detrusor instability due to neurogenic bladder. In certain cases, oxybutynin may be used to control bladder spasms triggered by indwelling ureteral stents or Foley catheters. This activity provides a comprehensive overview of oxybutynin's indications, mechanism of action, methods of administration, significant adverse effects, contraindications, monitoring, and toxicity. The activity also aims to equip the interprofessional healthcare team by enhancing their competence to direct patient therapy effectively, particularly when anticholinergic treatment is warranted for patients with overactive bladder.